Objectives. Etanercept 50 mg a week is approved in the treatment of AS. Increasing the etanercept dose to 100 mg/week improves efficacy in cutaneous psoriasis, a clinical manifestation related to the spondylarthritis family, while maintaining its safety profile. The purpose of this study was to evaluate the efficacy and safety of etanercept 100 vs 50 mg/week in patients with AS.
Introduction
AS is a chronic inflammatory disease characterized by axial and peripheral arthritis and enthesitis [1] , which affects between 0.15 and 1.4% of the adult population [2] . About 80% of patients experience their first symptoms before the age of 30 years, with a proportion men : women of 2 : 1. More than 90% of susceptibility to AS is explained by genetic factors, but environmental factors, such as bacterial infections, have also been identified [1, 3] . The first-choice treatment in AS is NSAIDs [4, 5] . However, 20% of patients do not improve with NSAIDs [5] . Other classic therapies in the treatment of rheumatic diseases, such as DMARDs or CSs, do not achieve an adequate control of disease activity [4, 6, 7] . Antagonists of TNF-a have been proved as a safe and effective alternative for AS, mainly for patients who are refractory to NSAIDs [3, 4] . TNF-a antagonists have a rapid effect on disease symptoms, normalizing acute-phase reactant levels and reducing inflammation in SI and spinal joints [3, 4] , and their effects are prolonged for a long time [4, 810] .
Etanercept is a fusion protein formed by a recombinant form of the human TNF soluble receptor p75, linked to the fragment crystallizable (Fc) portion of the human G1 immunoglobulin [11] . The safety and efficacy of etanercept in the treatment of AS has been proved in a large number of studies [9, 10, 1215] , and its use in AS treatment is approved in a regimen of 50 mg a week, both in Europe and in the USA. Adverse events related to etanercept are generally mild or moderate [9, 14] . Recently, several studies have been conducted increasing etanercept dose from 50 to 100 mg/week for the treatment of psoriasis and RA. However, the results of these studies showed that increasing etanercept dose did not improve its efficacy [1620] , while maintaining its safety profile. To date, no studies have been done to test the efficacy and safety of etanercept 100 mg/week in the treatment of AS. Thus, the purpose of the present double-blind, 12-week randomized pilot study, is to evaluate the effect of etanercept 100 vs 50 mg/week to treat AS as well as its safety and tolerability profile.
Patients and methods

Subjects
Eligible patients were recruited in 15 Spanish centres. The whole study was primarily approved by the local ethical review board of the Hospital de Navarra, and secondarily by the ethical review boards of all participating hospitals, according to the principles of the Declaration of Helsinki. All patients received detailed information on the study and provided their written informed consent before their inclusion. Candidates were adult outpatients (1870 years) with AS diagnosis as defined by the modified New York criteria for AS [21] , and with inflammatory activity maintained for >12 weeks, who had failed treatment with at least two NSAIDs at maximum recommended doses during at least 3 months. In patients with predominantly axial forms, inflammatory activity was defined by a BASDAI 54 and at least one of the following: patient's global disease assessment 54; spinal pain 54 on a visual analogue scale (VAS); and/or increase in ESR and/or CRP above normal laboratory levels. In patients with predominantly peripheral forms, inflammatory activity was defined by arthritis or enthesis in at least one site, together with patient's global disease assessment 54 and/or increase in ESR and/or CRP above normal laboratory levels. Women had a negative pregnancy test and, if sexually active, both men and women used medically acceptable contraceptive methods.
Patients with complete ankylosis of the spine were ineligible. Patients were also excluded if they had contraindications for the treatment with anti-TNF, or if they needed to start treatment with DMARDs or with prednisone (or equivalent) >10 mg/day. Other non-permitted treatments were more than one NSAID in the 2 weeks before baseline, IA CSs or any live vaccine in the 4 weeks before the screening visit, any investigational drug within 3 months of the screening visit, and TNF-a inhibitors or other biological drugs at any time. Abnormalities in haematological profiles, important concomitant medical conditions, psoriasis, psychiatric disease, or history of alcohol or drug abuse, were reasons for exclusion. Pregnant or breastfeeding women were also ineligible. Previous history of uveitis was not an exclusion criterion.
Randomization and treatment
Patients were sequentially numbered at the screening visit. Upon completion of the baseline evaluation, eligible subjects were randomly allocated to a treatment group. Patients remained in their treatment group until the end of the study. All study personnel and participants, including statisticians, were blinded to treatment assignment for the whole duration of the study.
Patients were randomly selected to receive either etanercept 50 mg twice a week (biw) or 50 mg once a week (qw) plus a second injection of placebo. At the baseline visit, patients were instructed about the reconstitution of the vials and self-administration of the treatment. Each dose was injected at a different site, including abdomen, thigh or upper arm, at the same hour of the day (±4 h) and on the same day of the week [every 72 (±24 h)]. No adjustments in the dose of etanercept were permitted; however, temporary suspension due to adverse events was permitted for up to 2 weeks. Changes in concomitant treatments were not allowed.
Study objectives
Our main aim was to evaluate the efficacy of etanercept 50 mg biw vs 50 mg qw in patients with AS who had previously failed the standard therapies. Time to treatment's initial response, the effect on the response criteria, and the safety and tolerability profile of the two treatment regimens were secondary objectives of this study.
Efficacy endpoints
The primary efficacy endpoint was the proportion of subjects who achieved Ankylosing Spondylitis Assessment www.rheumatology.oxfordjournals.org Study (ASAS20) [22] response at Week 12. Patients' global assessment of disease activity and pain were measured using a VAS, physical function was assessed using the BASFI score [23] and inflammation was measured using the score of the morning-stiffness items of the BASDAI [24] . Secondary endpoints were the proportion of subjects who achieved ASAS40, ASAS50, ASAS70 [25] , ASAS5/6 [26] response and partial remission at Week 12, nocturnal and overall spine pain, physician global assessment of disease activity, activity index (BASDAI), spinal mobility (BASMI) score [27] , complete peripheral joint count (ACR64/66 index), tenderness of enthesis [Maastricht Ankylosing Spondylitis Enthesis Score (MASES) index] [28] , CRP and ESR. Finally, quality of life was assessed by the European Quality of Life Scale (EuroQoL) [29] and 36-item Short-Form Health Survey (SF-36) questionnaires [30] .
Safety endpoints
Safety was assessed by the evaluation of the percentage and type of adverse events and serious adverse events, vital signs, physical examination, early withdrawals and laboratory results. Safety was assessed during all the study, until 15 days after the last study visit. All patients who received at least one etanercept dose were included in the safety analysis.
Sample size
In order to determine and assess response in terms of ASAS20 at 12 weeks of treatment with etanercept 100 vs 50 mg/week, 108 patients were enrolled, 54 per arm. This sample size was calculated to allow to detect differences of at least 25% between treatments (P = 0.05, two-sided, 80% contrast power). A 10% replacement rate was estimated.
Statistical methods
All randomized patients who had received at least one treatment dose and who had undergone at least one therapy evaluation were included in the intent-to-treat (ITT) population. Of them, those who fulfilled study procedures without major deviations and received at least 80% of injections (at least 19) were considered as per-protocol (PP) population. Efficacy and safety analysis were performed on the ITT population. Furthermore, the primary efficacy endpoint was also analysed in the PP population.
Qualitative variables were described using absolute and relative frequencies; quantitative variables by means of centralization and dispersion measures. To determine changes from the baseline visit in each primary endpoint, association tests were performed between visits using the Wilcoxon test for continuous variables, the McNemar test for discreet dichotomic variables or the Sign test for non-dichotomic ordinal discreet variables. Responders' rate was evaluated in terms of ASAS after 12 weeks of treatment. Two-sided significance tests (P = 0.05) were used.
Results
Data were collected between January 2007 and March 2008. Out of 126 screened patients, 108 were randomly selected and treated, 54 in each arm of the study. Of them, 97 were considered PP population (Fig. 1) . The reasons for the exclusion of 11 patients from PP analysis were protocol deviations (7 patients), adverse events (2 patients), patient decision (1 patient) and other reasons (1 patient). The number of received injections and weeks on treatment were equivalent between groups.
Patient's demographics are shown in Table 1 . Baseline and Weeks 2 and 12 clinical data are summarized in Table 2 . Baseline differences between groups were only found in HLA-B27, which was more frequently found among patients assigned to etanercept 50 mg biw (P = 0.04). Baseline quality of life and changes at Week 12 are summarized in Table 3 . The eight dimensions of the SF-36 questionnaire were reduced to two dimensions: a physical component summary (PCS) score and a mental component summary (MCS) score. EuroQoL results were categorized in patients with problems and patients without problems. No significant differences were found between groups in baseline quality of life.
Efficacy
In the ITT analysis, at Week 12, ASAS20 response was achieved by 34 (71%) out of 48 patients of the etanercept 50 mg biw group and by 37 (76%) out of 49 patients of the etanercept 50 mg qw group (Fig. 2A) . The differences were not statistically significant. Similarly, ASAS40, ASAS50, ASAS70 and ASAS5/6 responses were not significantly different between both groups ( Fig. 2A) . At 12 weeks, partial remission was achieved by 14 (29%) out of 48 patients of the etanercept 50 mg biw group and by 13 (27%) out of 49 patients of the etanercept 50 mg qw group. Per PP population analysis of ASAS20 response gave similar results, without significant differences. ASAS responses at Week 2 are shown in Fig. 2B .
The values at Weeks 2 and 12 for nocturnal and overall spinal pain, patient and physician global assessment, BASFI, BASDAI, BASMI, swollen and painful joint count, MASES index, CRP and ESR are summarized in Table 2 . BASDAI scores at all visits are shown in Fig. 3A . All parameters were significantly reduced at Week 2 (P < 0.05 or 0.0001) in both treatment groups. Exceptions were found in the etanercept 50 mg biw group for BASMI and the number of painful joints, which were significantly reduced at Week 4, and for the number of swollen joint counts, which was significantly reduced at Week 8. The proportion of patients reaching a 50% improvement in the BASDAI score at Week 2 was 53% in patients treated with etanercept 50 mg biw and 43% in patients treated with etanercept 50 mg qw (Fig. 3B) . These proportions increased to 67 and 63% for etanercept 50 mg biw and etanercept 50 mg qw, respectively, at Week 12. No significant differences were found in any efficacy endpoint between treatment groups.
Changes in quality of life from baseline to Week 12 are shown in Table 3 . Both the SF-36 questionnaire and the EuroQoL index score showed a significant improvement at Week 12 (P < 0.0001). No significant differences between groups were found except for the EuroQoL paindiscomfort domain, in which the patients in the etanercept 50 mg biw group had more problems (P = 0.0461).
Safety
The safety population included all patients who received at least one etanercept dose. Fifty-six patients experienced at least one adverse event, 28 in each treatment group. In the etanercept 50 mg biw group, 25 out of 28 adverse events were related to treatment, and 18 out of 28 in the etanercept 50 mg qw group. In total, 101 adverse events were reported, 51 in patients treated with etanercept 50 mg biw and 50 in patients treated with etanercept 50 mg qw. Out of them, 87 (86%) were mild, 9 (9%) were moderate and 5 (5%) were severe (Table 4) . No differences were found between groups. Adverse events with a frequency of >3% are shown in Table 4 . The most common adverse events were infections and infestations (11out of 54 in etanercept 50 mg biw and 14 out of 54 in etanercept 50 mg qw), gastrointestinal disorders (10 out of 54 in etanercept 50 mg biw and 4 out of 54 in etanercept 50 mg qw) and general disorders and administration site conditions (7 out of 54 in etanercept 50 mg biw and 10 out of 54 in etanercept 50 mg qw). Considering only treatment-emergent adverse events, the most frequent were injection-site reactions (7 out of 54 in etanercept 50 mg biw and 8 out of 54 in etanercept 50 mg qw); all of them mild.
Three patients suffered serious adverse events. One patient on etanercept 50 mg biw suffered diarrhoea with abdominal pain and distension. Therefore, the treatment was temporarily suspended and uneventfully reintroduced after recovery. In the etanercept 50 mg qw group, one patient experienced severe acute diarrhoea and one a viral respiratory infection; both patients were withdrawn from the study. Additionally, one patient experienced a pneumothorax during screening not related to treatment, and was not selected. All serious adverse events resolved uneventfully. Mild haematological abnormalities were found in three patients, but all of them resolved spontaneously.
Abnormal liver enzyme levels were detected in eight patients during the study, four in each treatment group. One additional patient had increased aspartate aminotransferase (AST) levels at baseline. All cases remitted without adjustments in treatment. Additionally, one patient with previous history of uveitis and who was receiving etanercept 50 mg biw had a flare of uveitis that was managed with topical CSs.
Discussion
The results of this study show that the use of etanercept in patients with AS, both in two weekly 50 mg doses and in one weekly 50 mg dose, improves disease activity, physical function and quality of life. However, the administration of etanercept 100 mg/week did not produce a significant improvement in AS symptoms as compared Missing data from two or less patients. *P < 0.01 vs baseline. **P < 0.001 vs baseline. ***P < 0.05 between groups.
www.rheumatology.oxfordjournals.org with the standard dose. Although there are several studies supporting the lack of efficacy of the increasing doses of the TNF-a antagonists in different chronic rheumatic diseases [1620], this is the first one to focus on the evaluation of the efficacy of increasing doses of a TNF-a antagonist (etanercept) for axial symptoms. In past years, it has been proved that the administration of etanercept 50 mg in two weekly 25 mg doses produces a dramatic and sustained improvement in AS symptoms. Davis et al. [13] and Calin et al. [14] tested the efficacy of etanercept 50 mg/week vs placebo at 12 weeks. In both studies, the proportion of patients achieving ASAS20 response was higher among those receiving etanercept than in those treated with placebo, with significant results as early as Week 2. Other studies [9, 10] showed that the percentage of ASAS20 responders increased >80% up to 192 weeks. In our study, >70% of patients achieved ASAS20 response after 12 weeks of etanercept treatment. Although no direct comparison is possible, those results are better than those reported in other studies on AS with infliximab [31] and adalimumab [32] and similar to those reported for golimumab [33] . In accordance with previous studies [13, 14] , in our study, ASAS50 response was achieved between 28 and 37% of patients (depending on the etanercept dose) at Week 2 and by >45% of patients at Week 12. ASAS40 response was achieved between 34 and 45% of patients at Week 2 and by >50% of patients at Week 12, whereas partial remission was achieved by 17% of patients at Week 2 and by 28% of patients at Week 12. Those results are slightly better than those reported for adalimumab [32, 34] and infliximab [31] . Other efficacy measures also improved in both groups of treatment, including nocturnal and global back pain, patient and physician global assessment, BASFI, BASDAI, BASMI, FIG. 3 (A) BASDAI score along visits. (B) Percentage of patients achieving BASDAI 50% along visits. swollen and painful joint count, MASES index, CRP and ESR. Moreover, improvements in BASDAI, physician global assessment, nocturnal back pain and painful joint count at Week 12 were higher for etanercept 50 mg than those reported for adalimumab in van der Heijde et al. [31] and Rudwaleit et al. [32] .
The efficacy of high-dose etanercept in psoriasis has been assessed in several studies [1618] . In a recent study [18] including more than 700 patients [psoriasis randomized etanercept study in subjects with psoriatic arthritis (PRESTA) study] comparing the efficacy of different doses of etanercept in PsA, etanercept 100 mg/week was significantly more efficacious than etanercept 50 mg/ week to treat skin symptoms. However, it did not seem to provide additional advantage in treating joint or enthesal symptoms. The efficacy of high-dose etanercept has also been tested in patients with RA. Johnsen et al. [20] compared the efficacy of etanercept 50 vs 100 mg/week administered in monotherapy to 77 patients with active RA, who were naïve to TNF-a antagonists. Later, Weinblatt et al. [19] compared standard vs high etanercept doses in 201 patients with suboptimal response to standard etanercept dose. None of the studies could find significant differences in treatment outcomes between patients treated with etanercept 50 and 100 mg/week. Therefore, these results are consistent with the results of load dosis of etanercept in AS (LOADET) study. However, PsA, RA and AS are different diseases with particular physiopathology and symptoms, which could have led to differences in the outcomes to high etanercept doses. In this regard, although AS can show some peripheral swollen or tender joints, the patients recruited in this study had few of such symptoms. This could have hindered the significance of the differences between etanercept doses, but the studies of Weinblatt et al. [19] and Johnsen et al. [20] included patients with a high peripheral disease activity, and neither found any differences between treatment doses.
Consistently with the results obtained in psoriasis [1618] and RA [19, 20] high-dose etanercept studies, in our work no differences were found between groups in the number and severity of adverse events; most of them being mild or moderate. In the PRESTA study [18] , 4% of the patients receiving high-dose etanercept and 3% of patients receiving 50 mg/week had serious treatmentemergent adverse events. However, in our study only 1 out of 54 patients treated with 50 mg biw and 2 out of 54 patients treated with 50 mg qw had serious adverse events. The most frequent adverse events found in previous high-dose etanercept studies [1618] were injectionsite reactions, headache and upper respiratory infections. Equally, in our study the most frequent adverse events found were injection-site reactions and upper respiratory infections, without significant differences between groups. The occurrence of uveitis in our study was much lower than that observed in the previous studies [9, 10, 13] . Only one patient, with previous history of uveitis, on etanercept 100 mg/week, reported this manifestation. Therefore, considering all the adverse events found in the present study, high-dose etanercept was shown to be as safe as the standard dose in the treatment of AS. Quality of life consistently improved in all domains for both etanercept doses; significant differences between doses were only found in the paindiscomfort domain. However, these results are difficult to interpret.
In conclusion, the administration of high-dose etanercept (100 mg/week) in the treatment of AS for 12 weeks did not lead to significant improvement in AS symptoms as compared with the standard dose.
Rheumatology key messages
. High-dose etanercept in 12-week AS treatment did not significantly improve symptoms, as against the standard dose. . High-dose etanercept in 12-week AS treatment was as safe as the standard dose. 
